It is worth noting that another phase I clinical trial is underway to evaluate the clinical efficacy of EGFR monoclonal antibody, cetuximab and levatinib in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.